EUVIMEDEUVIMED entdecken
Open Access

Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants

Brittni A Scruggs iD, Aubrey Berger iD, Travis Knudsen, Francesca N Kopp, Matthew Hill, Emma Trncic iD, Kjersten Anderson, Raymond Iezzi iD, Alan D Marmorstein iD

Science Advances · 05.09.2025 · 11 (36)

DOI: 10.1126/sciadv.adv7922 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 05.09.2025. Verfasst von Brittni A Scruggs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Dependovirus, Hydrogels, Genetic Therapy, Fibrin. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Subretinal injection of adeno-associated virus (AAV) is generally more efficacious and less inflammatory than intravitreal injection for retinal gene therapy. However, adverse events (e.g., chorioretinal atrophy) have been reported in many patients receiving subretinal injection of Luxturna (voretigene neparvovec-rzyl) and experimental gene therapies. Subretinal injection confines transduction to the treated area. To address this, we manufactured high-concentration fibrin hydrogels encapsulating AAV2–green fluorescent protein (AAV2- GFP ). Gels had homogeneous AAV distribution, desired mechanical properties, and retained infectivity. Epiretinal placement of fibrin–AAV2- GFP ( n = 11) was compared to subretinal ( n = 5) and intravitreal AAV2- GFP injection ( n = 3). The subretinal group exhibited inconsistent retinal pigment epithelium (RPE) transduction restricted to the injection region with severe atrophy in two cases. The intravitreal group had weak transduction and inflammation. In contrast, epiretinal hydrogels degraded within days and led to broad transduction of RPE without atrophy or inflammation. This technology could advance gene therapy for retinal degenerations and other ocular or systemic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DependovirusHydrogelsGenetic TherapyFibrinRetinaHumansAnimalsRetinal Pigment EpitheliumGenetic VectorsGreen Fluorescent ProteinsIntravitreal InjectionsTransduction, Genetic

Substanzen

HydrogelsFibrinGreen Fluorescent Proteins

Autor:innen und Institutionen

  • Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.
  • Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.
  • Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Brittni A Scruggs, Aubrey Berger, Emma Trncic, Raymond Iezzi, Alan D Marmorstein

Zitieren

APA

Scruggs, B. A., Berger, A., Knudsen, T., Kopp, F. N., Hill, M., Trncic, E., Anderson, K., Iezzi, R., & Marmorstein, A. D. (2025). Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants. Science Advances, 11(36). https://doi.org/10.1126/sciadv.adv7922

Vancouver

Scruggs BA, Berger A, Knudsen T, Kopp FN, Hill M, Trncic E, et al. Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants. Science Advances. 2025;11(36). doi:10.1126/sciadv.adv7922

BibTeX
@article{Scruggs2025,
  author = {Scruggs, Brittni A and Berger, Aubrey and Knudsen, Travis and Kopp, Francesca N and Hill, Matthew and Trncic, Emma and Anderson, Kjersten and Iezzi, Raymond and Marmorstein, Alan D},
  title = {Retinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {36},
  doi = {10.1126/sciadv.adv7922}
}
Kostenlos starten →